Guardant Health stock
GHNASDAQGuardant Health, Inc., HealthcareISIN US40131M1099
45Score 45 out of 100, Weak
Price and trend
68 / 100
Price history
+58% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since November 2024 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 45).
The price is 17% below its 52-week high. Largest decline in 8 years: 91% (February 2021 to April 2024).
Chart figures for advanced users
- SMA 50$169.00
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$132.35
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)45
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$78.60
- The lowest closing price of the last twelve months.
- Resistance$187.22
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Guardant Health, Inc. belongs to the Medical (Diagnostics & Research) industry (United States) and, with a market value of $20.94B, is number 13 of 37 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $982.02M (up 32.9% year on year) and a loss of $416.28M.
- For fiscal 2026, analysts expect on average revenue of $1.37B (up 39.1%) and adjusted earnings per share of −$3.38.
Show more
- MEQIRI Score 45 out of 100 (Weak): rank 464 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 27.9% a year since 2020, Medical (Diagnostics & Research) median 6.6%.Growth 70
Weaknesses
- DilutionShare count up 29% since 2020.Capital allocation 18
- Loss-makingLoss of $485.07M over the last 12 months.Fundamentals 17
- Negative free cash flowFree cash flow −$232.15M over the last 12 months.Fundamentals 17
Its standout strengths are momentum and growth, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredA fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 41.7% on the twelve months before. Revenue has grown strongly since 2016, at around 50% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 64%, operating −45%, net −42%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Feb 2027in 98 days
- Last reported
- 5 Nov 2026EPS reported −$0.29 (expected −$0.75)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.4% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- −$3.38−4.0%
- Revenue
- $1.37B+0.6%
- Earnings per share
- −$2.18−7.4%
- Revenue
- $1.84B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +12.4%2026 revenue guidance raised to $1.34 billion to $1.36 billion (up 36% to 38%); free cash flow burn is $10 million higher at $195 million to $205 million due to capacity investments.
“We are raising full year 2026 revenue guidance to a range of $1.34 billion to $1.36 billion, representing growth of 36% to 38%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 30 Jul 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 15 insiders sold, $97.38M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Tariq MusaSale
16 Oct 2026, Board
- Shares
- 116
- Price
- $165.88
- Value
- $19,242
- Azar Alex M IISale
14 Oct 2026, Board
- Shares
- 69
- Price
- $159.89
- Value
- $11,032
- Krognes Steve E.Sale
16 Sept 2026, Board
- Shares
- 6,674
- Price
- $175.74
- Value
- $1.17M
Show 30 more
- Azar Alex M IISale
16 Sept 2026, Board
- Shares
- 826
- Price
- $175.00
- Value
- $144,550
- Tariq MusaSale
16 Sept 2026, Board
- Shares
- 116
- Price
- $175.00
- Value
- $20,300
- Chudova DaryaSale
15 Sept 2026, Chief Technology Officer
- Shares
- 7,738
- Price
- $178.00
- Value
- $1.38M
- Kalia KumudSale
11 Sept 2026, Chief Information Officer
- Shares
- 4,000
- Price
- $158.05
- Value
- $632,193
- Talasaz AmirAliSale
21 Aug 2026, Co-Chief Executive Officer
- Shares
- 37,500
- Price
- $169.16
- Value
- $6.34M
- Tariq MusaSale
17 Aug 2026, Board
- Shares
- 116
- Price
- $156.45
- Value
- $18,148
- Monroe Terilyn J.Sale
12 Aug 2026, Chief People Officer
- Shares
- 46,300
- Price
- $165.12
- Value
- $7.65M
- Freeman ChrisSale
10 Aug 2026, Chief Commercial Officer
- Shares
- 63,605
- Price
- $169.58
- Value
- $10.79M
- Hidalgo Medina ManuelSale
5 Aug 2026, Board
- Shares
- 1,700
- Price
- $164.24
- Value
- $279,202
- Clark Ian TSale
4 Aug 2026, Board
- Shares
- 14,180
- Price
- $158.92
- Value
- $2.25M
- Tariq MusaSale
16 Jul 2026, Board
- Shares
- 116
- Price
- $163.29
- Value
- $18,942
- Talasaz AmirAliSale
29 Jun 2026, Co-Chief Executive Officer
- Shares
- 143,028
- Price
- $151.54
- Value
- $21.67M
- Talasaz AmirAliSale
26 Jun 2026, Co-Chief Executive Officer
- Shares
- 116,972
- Price
- $150.79
- Value
- $17.64M
- Tariq MusaSale
22 Jun 2026, Board
- Shares
- 1,951
- Price
- $131.16
- Value
- $255,893
- Potter Myrtle SSale
22 Jun 2026, Board
- Shares
- 1,556
- Price
- $131.16
- Value
- $204,085
- Tariq MusaSale
16 Jun 2026, Board
- Shares
- 116
- Price
- $130.19
- Value
- $15,102
- Kalia KumudPurchase
15 Jun 2026, Chief Information Officer
- Shares
- 600
- Price
- $130.76
- Value
- $78,456
- Kalia KumudSale
15 Jun 2026, Chief Information Officer
- Shares
- 600
- Price
- $131.08
- Value
- $78,648
- Kalia KumudSale
11 Jun 2026, Chief Information Officer
- Shares
- 3,418
- Price
- $130.24
- Value
- $445,156
- Kalia KumudSale
10 Jun 2026, Chief Information Officer
- Shares
- 600
- Price
- $130.86
- Value
- $78,516
- Kalia KumudSale
10 Jun 2026, Chief Information Officer
- Shares
- 5,000
- Price
- $130.41
- Value
- $652,030
- Eltoukhy HelmySale
5 Jun 2026, Co-Chief Executive Officer
- Shares
- 100,000
- Price
- $126.30
- Value
- $12.63M
- Bell Michael BrianSale
5 Jun 2026, Chief Financial Officer
- Shares
- 2,000
- Price
- $128.62
- Value
- $257,241
- Krognes Steve E.Sale
4 Jun 2026, Board
- Shares
- 9,294
- Price
- $132.51
- Value
- $1.23M
- Joyce Meghan V.Sale
3 Jun 2026, Board
- Shares
- 10,000
- Price
- $126.98
- Value
- $1.27M
- Hidalgo Medina ManuelSale
28 May 2026, Board
- Shares
- 1,000
- Price
- $130.06
- Value
- $130,060
- Saia John G.Sale
27 May 2026, Chief Legal Officer
- Shares
- 10,000
- Price
- $125.08
- Value
- $1.25M
- Freeman ChrisSale
22 May 2026, Chief Commercial Officer
- Shares
- 24,406
- Price
- $118.67
- Value
- $2.9M
- Saia John G.Sale
20 May 2026, Chief Legal Officer
- Shares
- 20,000
- Price
- $106.51
- Value
- $2.13M
- Talasaz AmirAliSale
20 May 2026, Co-Chief Executive Officer
- Shares
- 36,756
- Price
- $106.05
- Value
- $3.9M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Guardant Health
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 45
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Diagnostics & Research)
The next larger and next smaller companies by market value
- Mettler-Toledo InternationalMTD $35.04B76
- IlluminaILMN $32.2B70
- Labcorp HoldingsLH $30.23B64
- Quest DiagnosticsDGX $28.55B69
- Medpace HoldingsMEDP $18.59B83
- RevvityRVTY $17.66B56
- Eurofins ScientificERF.PA $17B61
- Charles River Laboratories InternationalCRL $16.42B55
ETFs that hold Guardant Health
Held by 18 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 5.14% | 0.50% | €127.06M |
| Harbor Health Care UCITS ETF AccW311 | 3.54% | 0.89% | €11.61M |
| L&G Healthcare Technology & Innovation UCITS ETFXMLH | 1.85% | 0.49% | €318.39M |
Show 5 more
| iShares Healthcare Innovation UCITS ETF2B78 | 1.38% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.35% | 0.35% | €1.21B |
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 1.06% | 0.25% | €44.3M |
| HAN-GINS Tech Megatrend Equal Weight UCITS ETF AccT3KE | 0.77% | 0.59% | €96.5M |
| First Trust US Large Cap Core AlphaDEX UCITS ETFFTGU | 0.38% | 0.75% | €140.24M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 28 Feb 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.